Skip to main content
Download PDF

Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment

The Journal of Headache and Pain volume 8, pages 273–276 (2007)Cite this article

Abstract

The clinical efficacy in migraine was compared for oral and subcutaneous sumatriptan and naratriptan. Doses of the two administration forms were chosen as resulting in comparable blood concentrations. Subcutaneous administrations of the drugs were superior for efficacy than the oral forms. This most likely due to a quicker rise in blood concentrations after subcutaneous injections.. In designing new therapies for migraine one should aim at a quick absorption of the drug, which will probably result in an increased efficacy.

References

  1. Thomsen LL, Dixon R, Lassen LH et al (1996) 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 16:270–275, 10.1046/j.1468-2982.1996.1604270.x, 1:STN:280:DyaK28zosVWnsQ%3D%3D, 8792040

    Article  CAS  PubMed  Google Scholar 

  2. Sternieri E, Pinetti D, Coccia CP et al (2005) Pharmacokinetics of sumatriptan in non-responders and in adverse drug reaction reporting migraine patients. J Headache Pain 6:319–321, 10.1007/s10194-005-0220-z, 1:CAS:528:DC%2BD28XmvFGmurs%3D, 16362699

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Visser WH, Burggraaf and adverse J, Muller LM et al (1996) Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 60:452–460, 10.1016/S0009-9236(96)90202-7, 1:CAS:528:DyaK28XmvFWku7s%3D, 8873693

    Article  CAS  PubMed  Google Scholar 

  4. Saxena PR, Tfelt-Hansen P (2006) Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd Ed. Philadelphia: Lippincott Williams & Wilkins 469–503

    Google Scholar 

  5. Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60:1259–1287

    Article  CAS  PubMed  Google Scholar 

  6. Tfelt-Hansen P (1993) Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials. Cephalalgia 13:238–244, 10.1046/j.1468-2982.1993.1304238.x, 1:STN:280:DyaK3szos1Ogtw%3D%3D, 8397070

    Article  CAS  PubMed  Google Scholar 

  7. Humphrey PP (2007) The discovery of a new drug class for the acute treatment of migraine. Headache 47(Suppl 1):S10–S19, 10.1111/j.1526-4610.2007.00672.x, 17425704

    Article  PubMed  Google Scholar 

  8. Lacey LF, Hussey EK, Fowler PA (1995) Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 47:543–548, 10.1007/BF00193709, 1:CAS:528:DyaK2MXmtVWntL8%3D, 7768259

    Article  CAS  PubMed  Google Scholar 

  9. Dahlöf C, Hogenhuis L, Olesen J et al (1998) Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 5:469–477, 10.1046/j.1468-1331.1998.550469.x, 10210876

    Article  PubMed  Google Scholar 

  10. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/!D agonists) in acute migraine: a meta-analysis of 53 trials. Lancet 358:1668–1675, 10.1016/S0140-6736(01)06711-3, 1:CAS:528:DC%2BD3MXos1ajsro%3D, 11728541

    Article  CAS  PubMed  Google Scholar 

  11. International Headache Society Clinical Trial Subcommittee (2000) Guidelines for controlled trials of drugs in migraine. Second edition. Cephalalgia 20:765–786, 10.1046/j.1468-2982.2000.00117.x

    Article  Google Scholar 

  12. Oral Sumatriptan Dose Defining Study Group (1991) Sumatriptan — an oral dose defining study. Eur Neurol 31:300–305, 10.1159/000116632

    Article  Google Scholar 

  13. Mathew NT, Dexter J, Couch J et al (1992) Dose ranging efficacy of safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Study Group. Arch Neurol 49:1271–1276, 1:STN:280:DyaK3s%2FotVCktw%3D%3D, 1333181

    Article  CAS  PubMed  Google Scholar 

  14. Visser WH, Ferrari MD, Bayliss EM et al (1992) Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Cephalalgia 12:308–313, 10.1046/j.1468-2982.1992.1205308.x, 1:STN:280:DyaK3s%2Fks1GqsA%3D%3D, 1330318

    Article  CAS  PubMed  Google Scholar 

  15. Havanka H, Dahlöf C, Pop H et al (2000) Efficacy of naratriptan in the acute treatment of migraine: a dose-ranging study. Naratriptan S2BW2004 Study Group. Clin Ther 22:970–980, 10.1016/S0149-2918(00)80068-5, 1:CAS:528:DC%2BD3cXmsFSqtLw%3D, 10972633

    Article  CAS  PubMed  Google Scholar 

  16. Mathew NT, Asgharenjad M, Peykamian M, Laurenza A (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. Neurology 49:485–490

    Article  Google Scholar 

  17. Klassen A, Elkind A, Asgharnejad M et al (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. The Naratriptan S2WA3001 Study Group. Headache 37:640–645, 10.1046/j.1526-4610.1997.3710640.x, 1:STN:280:DyaK1c7gt1SksA%3D%3D, 9439085

    Article  CAS  PubMed  Google Scholar 

  18. Tfelt-Hansen P. Maximum effect of triptans in migraine? A comment. Cephalalgia, in press

  19. Volans GN (1974) Absorption of effervescent aspirin during migraine. BMJ 4:265–269, 10.1136/bmj.4.5939.265, 1:STN:280:DyaE2M%2Fjs1yjsQ%3D%3D, 4425854

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Tfelt-Hansen P, Young WB, Silberstein SD (2006) Antiemetics, prokinetics, neuroleptic and miscellaneous drugs in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 3rd Eds. Philadelphia: Lippincott Williams & Wilkins 505–513

    Google Scholar 

  21. Jhee SS, Shiovitz T, Crawford AW, Cutler NR (2001) Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 40:189–205

    Article  CAS  PubMed  Google Scholar 

  22. Sumatriptan Cluster Headache Study Group (1991) Treatment for acute cluster headache with sumatriptan. N Eng J Med 325:322–326, 10.1056/NEJM199108013250505

    Article  Google Scholar 

  23. Connor HE, Feniuk W, Beattie DT et al (1997) Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 17:145–152, 10.1046/j.1468-2982.1997.1703145.x, 1:STN:280:DyaK2szhtl2gtw%3D%3D, 9170336

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Danish Headache Centre Department of Neurology, University of Copenhagen Glostrup Hospital, DK-2600, Glostrup, Denmark

    Peer Tfelt-Hansen

Authors
  1. Peer Tfelt-Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peer Tfelt-Hansen.

Rights and permissions

Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Reprints and permissions

About this article

Cite this article

Tfelt-Hansen, P. Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment. J Headache Pain 8, 273–276 (2007). https://doi.org/10.1007/s10194-007-0411-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10194-007-0411-x

Keywords

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us